Generic name: doravirine 100mg, lamivudine 300mg, tenofovir disoproxil fumarate 300mg
Dosage form: tablet, film coated
Medically reviewed by Drugs.com. Last updated on Oct 1, 2020.
Testing When Initiating and During Treatment with DELSTRIGO
Prior to or when initiating DELSTRIGO, test patients for HBV infection [see Warnings and Precautions (5.1)].
Prior to or when initiating DELSTRIGO, and during treatment with DELSTRIGO, on a clinically appropriate schedule, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus [see Warnings and Precautions (5.2)].
DELSTRIGO is a fixed-dose combination product containing 100 mg of doravirine (DOR), 300 mg of lamivudine (3TC), and 300 mg of TDF. The recommended dosage of DELSTRIGO in adults is one tablet taken orally once daily with or without food [see Clinical Pharmacology (12.3)].
Because DELSTRIGO is a fixed-dose combination tablet and the dosage of lamivudine and TDF cannot be adjusted, DELSTRIGO is not recommended in patients with estimated creatinine clearance less than 50 mL/min [see Warnings and Precautions (5.2) and Use in Specific Populations (8.6)].
Dosage Adjustment with Rifabutin
If DELSTRIGO is co-administered with rifabutin, take one tablet of DELSTRIGO once daily, followed by one tablet of doravirine 100 mg (PIFELTRO) approximately 12 hours after the dose of DELSTRIGO for the duration of rifabutin co-administration [see Drug Interactions (7.2) and Clinical Pharmacology (12.3)].
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Frequently Asked Questions
More about Delstrigo (doravirine / lamivudine / tenofovir)
- Side Effects
- During Pregnancy
- Drug Images
- Drug Interactions
- Pricing & Coupons
- En Español
- Drug class: antiviral combinations
- FDA Approval History